Literature DB >> 2847992

Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.

P Y Holoye1, D T Carr, H M Dhingra, B S Glisson, J S Lee, W K Murphy, T Umsawasdi, D Jeffries.   

Abstract

Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderate.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2847992     DOI： 10.1007/bf00175401

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

Review 1.  Tiazofurin: a new antitumor agent.

Authors:  P J O'Dwyer; D D Shoemaker; H N Jayaram; D G Johns; D A Cooney; S Marsoni; L Malspeis; J Plowman; J P Davignon; R D Davis
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

2.  Novel nucleoside inhibitors of guanosine metabolism as antitumor agents.

Authors:  R M Smejkal; T T Page; V L Boyd; W L Nyhan; S J Jacobsen; J H Mangum; R K Robins
Journal:  Adv Enzyme Regul       Date:  1984

3.  Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase.

Authors:  A Fridland; M C Connelly; T J Robbins
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

4.  Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.

Authors:  J D Roberts; J A Stewart; J J McCormack; I R Krakoff; C A Culham; J N Hartshorn; R A Newman; L D Haugh; J A Young
Journal:  Cancer Treat Rep       Date:  1987-02

5.  Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  T J Melink; D D Von Hoff; J G Kuhn; M R Hersh; L A Sternson; T F Patton; R Siegler; D H Boldt; G M Clark
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701
  5 in total
  3 in total

Review 1.  New perspectives in lung cancer.5. New drugs in lung cancer.

Authors:  D C Talbot; I E Smith
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

Review 2.  Clinical toxicity associated with tiazofurin.

Authors:  J L Grem; L Rubinstein; S A King; B D Cheson; M J Hawkins; D D Shoemaker
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 3.  Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.

Authors:  Rand Naffouje; Punita Grover; Hongyang Yu; Arun Sendilnathan; Kara Wolfe; Nazanin Majd; Eric P Smith; Koh Takeuchi; Toshiya Senda; Satoshi Kofuji; Atsuo T Sasaki
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.